CALQUENCE ® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death…
First and only BTK inhibitor to demonstrate favorable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the ECHO Phase III trial showed AstraZeneca…
